ArticleJournal for immunotherapy of cancer2025

Temporal optimization of CD25-biased IL-2 agonists and immune checkpoint blockade leads to synergistic anticancer activity despite robust regulatory T cell expansion.

Irfan Baki Kilic et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.